Mary Ellen Perry, Ph.D., Program LeaderOffice of Strategic CoordinationDivision of Program Coordination, Planning, and Strategic InitiativesNIH Office of the Director

Special NIH Funding Opportunities

27 NIH Institutes and Centers27 NIH Institutes and Centers

Clinical Center

International Center

National Institute of Biomedical Imagingand Bioengineering

National Institute of Deafness and

Communications Disorders

National Institute of Diabetes and Digestive and Kidney Diseases

NIAMSNational Institute of Arthritis andMusculoskeletal and Skin Diseases

The Office of the Director (OD)

Francis S. Collins, M.D., Ph.D.NIH Director

Strategic Priorities1.High-throughput Technologies

2.Translational Medicine

3.Science for Health Care Reform

4.Global Health

5.Reinvigorating and Empowering the Biomedical Research Community

Established:

the Common Fund to support cross-cutting, trans-NIH programs

the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI)

In FY2010, the Common Fund was $544M.

The Common Fund currently supports a series of short term, high impact, trans-NIH programs, some of which were previously called Roadmap programs.

James M. Anderson, M.D., Ph.D.DPCPSI Director

7

2009 BC

Five Special Funding Opportunities

Eureka!

Reinvigorating and Empowering the Biomedical Research Community

We must develop ways to liberate our brightest minds to

pursue high-risk, high-reward ideas during their most creative years.

Nature, Vol.467, 7 October 2010.

Age

Per

cen

t o

f T

ota

lAge Distribution of R01-equivalent Principal Investigators

All Investigators First-Time Investigators

Average Age

All Investigators 51.0

First-Time Investigators 42.6

FY2007 Data

How can we shorten the time to first grant?How can we shorten the time to first grant?

GRADUATE/GRADUATE/MEDICALMEDICALSTUDENTSTUDENT

POSTPOSTDOCTORALDOCTORAL

EARLYEARLY

MIDDLEMIDDLE

SENIORSENIOR

CA

RE

ER

CA

RE

ER

GRADUATE/GRADUATE/MEDICALMEDICALSTUDENTSTUDENT

EARLYEARLY

MIDDLEMIDDLE

SENIORSENIOR

CA

RE

ER

CA

RE

ER

Early Independence Award Program

• Graduate students and clinicians within one year of degree

• Up to $250K DC/year for five years, plus F&A

• Talented young scientists who have the intellect, scientific creativity, drive and maturity to flourish independently without the need for traditional post-doctoral training

• FOA RM10-019

• January 21, 2011 receipt12

http://nihroadmap.nih.gov/

Transformative R01 program places the emphasis on creative ideas - projects with the potential to create or overturn paradigms (62 awards since 2009).

Pioneer Awards support individual scientists of exceptional creativity who propose pioneering approaches to major challenges in biomedical and behavioral research (98 awards since 2004).

New Innovator program addresses two important goals: stimulating highly innovative research and supporting promising new investigators (167 awards since 2007).

Reinvigorating and Empowering the Biomedical Research Community

http://nihroadmap.nih.gov/

14

New Innovator Award

• Unusually creative investigators with a highly innovative research idea

• $300K DC/year for five years, plus F&A

• New and early stage investigators

• FOA RM10-009

• Due date September 20, 2010

452 applications

http://nihroadmap.nih.gov/

15

Benjamin Garcia

Princeton University

Novel Methodology for Quantitative High-throughput Cancer Epigenetics

Conor Evans

Massachusetts General Hospital/Harvard Medical School

Imaging and Overcoming Hypoxia-Induced Resistance in Metastatic Ovarian Cancer

Jianjun Cheng

University of Illinois at Urbana-Champaign

Developing Clinically Applicable, Cancer-Targeting Polymeric Nanoconjugates

New Innovators in cancer research

Monica Guzman

Cornell University /Weill Medical College

Selection of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem Cells

http://nihroadmap.nih.gov/

16

Pioneer Award Program

• Any qualified investigator

• $500K DC/year for five years, plus F&A

• Individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges

• FOA RM10-008

• Due date September 13, 2010

http://nihroadmap.nih.gov/

240 applications

17

Some Pioneers of interest

Michael Roukes

California Institute of Technology

Nanoscale Tools to Push Biomedical Frontiers

Susan Rosenberg

Baylor College of Medicine

Forward Genomics of Damage Control: An Undiscovered Class of Cancer Genes

Leona Samson

Massachusetts Institute of Technology

Developing Novel Methods to Measure DNA Repair Capacity in Human Populations

Joseph Nadeau

The Institute for Systems Biology

Lamarck Redux: Transgenerational Genetic Effects on Phenotypes and Disease

http://nihroadmap.nih.gov/

18

Transformative RO1

• Anyone with a project to overturn or create a paradigm

• Up to $25M TC for five years

• “Out of the box” ideas

• FOA RM10-010

• October 27, 2010 receipt

http://nihroadmap.nih.gov/

19

Some TRO1 projects of interest

GEORGE COUKOS

University of Pennsylvania

Transformative Personalized Vascular Disrupting Cancer Immunotherapy

RICHARD FLAVELLMADHAV DHODAPKARMARKUS MANZ

Yale University and University Hospital Zurich

Understanding Hematopoietic Neoplasias Using Humanized Mice

http://nihroadmap.nih.gov/

Transformative R01 Program places the emphasis on creative ideas—projects with the potential to create or overturn paradigms. (62 awards since 2009).

Pioneer Awards support individual scientists of exceptional creativity who propose pioneering approaches to major challenges in biomedical and behavioral research (98 awards since 2004).

New Innovator Program address two important goals: stimulating highly innovative research and supporting promising new investigators (167 awards since 2007).

Reinvigorating and Empowering the Biomedical Research Community

We WILL have all 3competitions again next year!

Look for announcements next spring.

http://nihroadmap.nih.gov/

Trans-NIH but not Common Fund

Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Program

• Open to anyone with a high impact project

• “Exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or bio-behavioral research”

• Up to $800K DC for four years, plus F&A

• FOA GM10-009

• November 24, 2010 receipt

21

22

Institutes participating in EUREKA awards

23

                 

Ravi Bellamkonda, Ph.D.Georgia Institute of Technology

“Our plan is to deliver the tumor to the drug -- by directing tumor cells to a specially engineered gel that can be removed or designed to kill the cells -- rather than the current strategy of delivering the drug to the tumor, which is problematic due to the irregular vasculature and poor diffusivity of the tumor tissue,” explained Bellamkonda, who is also a Georgia Cancer Coalition Distinguished Scholar.

NCI Eureka awardee 2010

24

Summary Special Opportunities

Early Independence Award Graduate student or new clinician

New Innovator New PI/ESI with innovative project

Pioneer Very creative investigator

TR01 Person with paradigm – disrupting idea

Eureka award Person with a very innovative project

Program Eligibility

25

26

For more information:

Contact information:

Today’s talk – Mary Ellen Perry perryma@mail.nih.gov

Pioneer, TR01, New Innovators, Early Independence Award – Ravi Basavappa basavapr@od.nih.gov

Eureka awards – Judy Mietz mietzj@mail.nih.gov

Common Fund – Ellie Murcia murciae@od.nih.gov

http://nihroadmap.nih.gov/